Table 3. Predicted and observed renal clearances (mL/min) of drugs by three methods.
| Drugs | Age | Observed CL | Predicted CL | ||
|---|---|---|---|---|---|
|
| |||||
| Method I | Method II | Method III | |||
| Acyclovir | 0–3 months | 5.1±1.9 | 6.0 | 6.9 | 6.3 |
| Cilastatin | Term | 1.4±0.3 | 1.3 | 1.3 | 1.3 |
| Cilastatin | Preterm | 0.3±0.1 | 0.4 | 0.4 | 0.4 |
| Cimetidine | Term | 6.8±NR | 5.5 | 6.0 | 5.7 |
| Famotidine | Preterm-term | 11.7±1.3 | 7.5 | 8.7 | 7.9 |
| Famotidine | 0–3 months | 4.0±NR | 3.0 | 3.0 | 3.0 |
| Mezlocillin | Preterm | 1.3±0.6 | 1.6 | 1.5 | 1.5 |
| Ranitidine | Term | 6.9±6.6 | 8.8 | 9.4 | 9.0 |
Method I: Allometric exponent derived from tubular secretary capacity, Method II: Minimal physiological model based on kidney weight, KBW, and GFR, Method III: Model based on kidney weight and KBW. NR: Not reported, GFR: Glomerular filtration rate, KBW: Kidney blood flow, CL: clearance